Abstract
Aim: The research was carried out to develop the microemulsion-loaded gel of curcu-min, alkylpolyglucoside, and tea tree oil to treat vulvovaginal candidiasis infection.
Methods: Screening of oils, surfactants, and co-surfactants was done based on solubility studies and the construction of pseudo-ternary phase diagrams with curcumin. The microemulsion was characterized for globule size, zeta potential, viscosity, and thermodynamic stability. Ex-vivo studies were carried out using Franz diffusion cells. The antifungal activity of microemulsion-loaded hydrogel was evaluated using the cup plate method using Candida albicans ATCC 10231 in glucose yeast agar medium.
Results: The selected micro-emulsion consisted of curcumin 35μg/mL, IPM+TTO (1:1) 0.1 mL, Milcoside 100 + Acconon MC 8-2 EP NF 0.6-0.3 mL, phosphate buffer pH 4 160 mL showed maximum thermodynamic stability and exhibited lowest particle size and highest intensity. The viscosity of microemulsion-loaded gel was 11.2 pa.s. The surface tension of the microemulsion was measured by tensiometer and was found to be 26.07 mN/m. Antimicrobial susceptibility testing assay was done according to NCCLs assay protocol, and the EC50 value of our formulation was found to be 0.4465 μg/mL. In-vitro drug release and ex-vivo permeation studies showed 67.9% release in 420 minutes and 83.02% release in 360 minutes, respectively. An in-vitro irritation study concluded that there was no redness or irritation on goat mucosa.
Conclusion: The texture analysis test showed adhesiveness at -172.46 g s at - 4.60 adhesive force, and the peak load was 13.40 g. The microemulsion-loaded gel formulation can be a promising alternative to the marketed formulations available for vaginal yeast infections.
[http://dx.doi.org/10.3109/03639049709150553]
[http://dx.doi.org/10.1016/j.fertnstert.2004.01.025] [PMID: 15236978]
[http://dx.doi.org/10.1016/S0020-7292(00)00350-7] [PMID: 11118561]
[http://dx.doi.org/10.1016/j.ijpharm.2006.03.012] [PMID: 16621366]
[http://dx.doi.org/10.1016/S0195-6701(98)90135-9] [PMID: 9830588]
[http://dx.doi.org/10.1111/j.1464-5491.2004.01202.x] [PMID: 15154951]
[http://dx.doi.org/10.1093/jac/dkn488] [PMID: 19038979]
[http://dx.doi.org/10.1139/W10-117] [PMID: 21358761]
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b00507] [PMID: 30184431]
[http://dx.doi.org/10.3390/60100087]
[http://dx.doi.org/10.1046/j.1365-2672.2003.02059.x] [PMID: 12969301]
[http://dx.doi.org/10.5958/0974-360X.2015.00021.9]
[http://dx.doi.org/10.1016/j.jsps.2011.08.001] [PMID: 23960777]
[http://dx.doi.org/10.1208/s12249-008-9178-x] [PMID: 19148761]
[http://dx.doi.org/10.1111/jocd.12945] [PMID: 30980617]
[http://dx.doi.org/10.3390/ma14010086] [PMID: 33375434]
[http://dx.doi.org/10.22159/ijap.2017v9i4.17760]
[http://dx.doi.org/10.1111/j.1745-4565.2002.tb00334.x]
[http://dx.doi.org/10.1089/jop.2013.0114] [PMID: 24367973]
[http://dx.doi.org/10.1016/0732-8893(95)00252-9] [PMID: 8988762]
[http://dx.doi.org/10.1016/j.jpha.2015.11.005] [PMID: 29403965]
[http://dx.doi.org/10.1002/aoc.1782]
[http://dx.doi.org/10.1007/978-3-319-00714-4_11]
[http://dx.doi.org/10.1007/978-1-4939-1289-6_4]
[http://dx.doi.org/10.1080/03639045.2021.1879832] [PMID: 33493079]
[http://dx.doi.org/10.1016/j.ijbiomac.2020.07.072] [PMID: 32653376]